First validation of the Prostatype® P‐score in an Asian cohort: Improving risk stratification for prostate cancer
Abstract Objectives To evaluate the prognostic performance of the Prostatype® score (P‐score) in the Asian prostate cancer (PCa) cohort and to assess its ability to refine risk stratification compared to the National Comprehensive Cancer Network (NCCN) guidelines. This study aimed to determine wheth...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | BJUI Compass |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/bco2.70026 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850157395827752960 |
|---|---|
| author | See‐Tong Pang Po‐Hung Lin Emelie Berglund Lidi Xu I‐Hung Shao Kai‐Jie Yu Chin‐Hsuan Hsieh Tzu‐Hsuan Chang Yu Chen Wen‐Hui Weng Cheng‐Keng Chuang |
| author_facet | See‐Tong Pang Po‐Hung Lin Emelie Berglund Lidi Xu I‐Hung Shao Kai‐Jie Yu Chin‐Hsuan Hsieh Tzu‐Hsuan Chang Yu Chen Wen‐Hui Weng Cheng‐Keng Chuang |
| author_sort | See‐Tong Pang |
| collection | DOAJ |
| description | Abstract Objectives To evaluate the prognostic performance of the Prostatype® score (P‐score) in the Asian prostate cancer (PCa) cohort and to assess its ability to refine risk stratification compared to the National Comprehensive Cancer Network (NCCN) guidelines. This study aimed to determine whether the P‐score, previously validated in European populations, maintains its predictive accuracy in a genetically and clinically distinct high‐risk Asian cohort, where late‐stage diagnosis is more common. Patients and methods This retrospective study included 148 PCa patients diagnosed at Taiwan Chang Gung Memorial Hospital between 2012 and 2017. Of these, 56 had primary metastases at diagnosis. The P‐score was calculated based on gene expression in core needle biopsies and clinical data collected from patients' medical records. The primary endpoint was PCa‐specific mortality (PCSM). The secondary endpoints were adverse pathology (AP) and biochemical failure. Results The P‐score significantly outperformed NCCN in predicting PCSM, achieving a higher C‐index (0.90 vs. 0.73, P < 0.005), which reflects superior prognostic accuracy. Notably, 19.6% of patients were reclassified into different risk categories compared to NCCN, improving risk stratification and potentially altering treatment decisions for nearly one in five patients. The P‐score was also an independent predictor of adverse pathology (P = 0.003, AUC: 0.81) and biochemical failure (P = 0.03, AUC: 0.89). Conclusions This study validated the P‐score for the first time in a non‐European population, confirming its predictive power in an Asian high‐risk setting. The reclassification of 19.6% of patients suggests that the P‐score refines risk stratification beyond NCCN, offering a more precise distinction between favourable and unfavourable outcomes, enabling more informed treatment decisions. These findings highlight the global applicability of the P‐score and its potential to improve risk assessment and personalized treatment for PCa patients worldwide. |
| format | Article |
| id | doaj-art-248f752816d84c4c88a0943dae76f968 |
| institution | OA Journals |
| issn | 2688-4526 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | BJUI Compass |
| spelling | doaj-art-248f752816d84c4c88a0943dae76f9682025-08-20T02:24:13ZengWileyBJUI Compass2688-45262025-06-0166n/an/a10.1002/bco2.70026First validation of the Prostatype® P‐score in an Asian cohort: Improving risk stratification for prostate cancerSee‐Tong Pang0Po‐Hung Lin1Emelie Berglund2Lidi Xu3I‐Hung Shao4Kai‐Jie Yu5Chin‐Hsuan Hsieh6Tzu‐Hsuan Chang7Yu Chen8Wen‐Hui Weng9Cheng‐Keng Chuang10Division of Urology, Department of Surgery Chang Gung Memorial Hospital, Linkou Branch Taoyuan TaiwanDivision of Urology, Department of Surgery Chang Gung Memorial Hospital, Linkou Branch Taoyuan TaiwanProstatype Genomics AB Solna Stockholms Län SwedenProstatype Genomics AB Solna Stockholms Län SwedenDivision of Urology, Department of Surgery Chang Gung Memorial Hospital, Linkou Branch Taoyuan TaiwanDivision of Urology, Department of Surgery Chang Gung Memorial Hospital, Linkou Branch Taoyuan TaiwanDivision of Urology, Department of Surgery Chang Gung Memorial Hospital, Linkou Branch Taoyuan TaiwanDivision of Urology, Department of Surgery Chang Gung Memorial Hospital, Linkou Branch Taoyuan TaiwanDivision of Urology, Department of Surgery Chang Gung Memorial Hospital, Linkou Branch Taoyuan TaiwanDepartment of Chemical Engineering and Biotechnology and Graduate Institute of Biochemical and Biomedical Engineering National Taipei University of Technology Taipei TaiwanDivision of Urology, Department of Surgery Chang Gung Memorial Hospital, Linkou Branch Taoyuan TaiwanAbstract Objectives To evaluate the prognostic performance of the Prostatype® score (P‐score) in the Asian prostate cancer (PCa) cohort and to assess its ability to refine risk stratification compared to the National Comprehensive Cancer Network (NCCN) guidelines. This study aimed to determine whether the P‐score, previously validated in European populations, maintains its predictive accuracy in a genetically and clinically distinct high‐risk Asian cohort, where late‐stage diagnosis is more common. Patients and methods This retrospective study included 148 PCa patients diagnosed at Taiwan Chang Gung Memorial Hospital between 2012 and 2017. Of these, 56 had primary metastases at diagnosis. The P‐score was calculated based on gene expression in core needle biopsies and clinical data collected from patients' medical records. The primary endpoint was PCa‐specific mortality (PCSM). The secondary endpoints were adverse pathology (AP) and biochemical failure. Results The P‐score significantly outperformed NCCN in predicting PCSM, achieving a higher C‐index (0.90 vs. 0.73, P < 0.005), which reflects superior prognostic accuracy. Notably, 19.6% of patients were reclassified into different risk categories compared to NCCN, improving risk stratification and potentially altering treatment decisions for nearly one in five patients. The P‐score was also an independent predictor of adverse pathology (P = 0.003, AUC: 0.81) and biochemical failure (P = 0.03, AUC: 0.89). Conclusions This study validated the P‐score for the first time in a non‐European population, confirming its predictive power in an Asian high‐risk setting. The reclassification of 19.6% of patients suggests that the P‐score refines risk stratification beyond NCCN, offering a more precise distinction between favourable and unfavourable outcomes, enabling more informed treatment decisions. These findings highlight the global applicability of the P‐score and its potential to improve risk assessment and personalized treatment for PCa patients worldwide.https://doi.org/10.1002/bco2.70026biomarkersmortalityprostate cancerrisk stratificationtherapy |
| spellingShingle | See‐Tong Pang Po‐Hung Lin Emelie Berglund Lidi Xu I‐Hung Shao Kai‐Jie Yu Chin‐Hsuan Hsieh Tzu‐Hsuan Chang Yu Chen Wen‐Hui Weng Cheng‐Keng Chuang First validation of the Prostatype® P‐score in an Asian cohort: Improving risk stratification for prostate cancer BJUI Compass biomarkers mortality prostate cancer risk stratification therapy |
| title | First validation of the Prostatype® P‐score in an Asian cohort: Improving risk stratification for prostate cancer |
| title_full | First validation of the Prostatype® P‐score in an Asian cohort: Improving risk stratification for prostate cancer |
| title_fullStr | First validation of the Prostatype® P‐score in an Asian cohort: Improving risk stratification for prostate cancer |
| title_full_unstemmed | First validation of the Prostatype® P‐score in an Asian cohort: Improving risk stratification for prostate cancer |
| title_short | First validation of the Prostatype® P‐score in an Asian cohort: Improving risk stratification for prostate cancer |
| title_sort | first validation of the prostatype r p score in an asian cohort improving risk stratification for prostate cancer |
| topic | biomarkers mortality prostate cancer risk stratification therapy |
| url | https://doi.org/10.1002/bco2.70026 |
| work_keys_str_mv | AT seetongpang firstvalidationoftheprostatypepscoreinanasiancohortimprovingriskstratificationforprostatecancer AT pohunglin firstvalidationoftheprostatypepscoreinanasiancohortimprovingriskstratificationforprostatecancer AT emelieberglund firstvalidationoftheprostatypepscoreinanasiancohortimprovingriskstratificationforprostatecancer AT lidixu firstvalidationoftheprostatypepscoreinanasiancohortimprovingriskstratificationforprostatecancer AT ihungshao firstvalidationoftheprostatypepscoreinanasiancohortimprovingriskstratificationforprostatecancer AT kaijieyu firstvalidationoftheprostatypepscoreinanasiancohortimprovingriskstratificationforprostatecancer AT chinhsuanhsieh firstvalidationoftheprostatypepscoreinanasiancohortimprovingriskstratificationforprostatecancer AT tzuhsuanchang firstvalidationoftheprostatypepscoreinanasiancohortimprovingriskstratificationforprostatecancer AT yuchen firstvalidationoftheprostatypepscoreinanasiancohortimprovingriskstratificationforprostatecancer AT wenhuiweng firstvalidationoftheprostatypepscoreinanasiancohortimprovingriskstratificationforprostatecancer AT chengkengchuang firstvalidationoftheprostatypepscoreinanasiancohortimprovingriskstratificationforprostatecancer |